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Summary
 Background Chronic B-lymphatic leukaemia is one reason for the development of secondary 
immunodeﬁ ciency due to a decrease of antibody immune activity (hypogamma-
globulinaemia) and a decrease of T-cell immunity. Cryptococcosis is an infectious 
disease induced by Cryptococcus neoformans fungus. A high incidence was re-
vealed in immunocompromised patients, above all in patients with AIDS or with 
haematological malignancies usually with a primary focus in the lungs and with 
characteristic spread into the cerebral dura mater and rarely into the kidneys, 
prostate, liver, bones and skin.
 Aim The aim of the study was to report a case of fatal Cryptococcus neoformans men-
ingitis in an adult patient with chronic B-lymphatic leukaemia.
 Material/Methods It is a case study report of a 74-year-old man who presented with a four-year histo-
ry of B-CLL admitted to the Department of Clinical Haematology with suspected 
neuroinfection. Symptoms included headache and sleepiness. Diagnostic work-
up comprised neurological investigation, magnetic resonance imaging of the 
brain, lumbal puncture with microscopic, cytological and biochemical investiga-
tions of cerebrospinal ﬂ uid and investigations of blood serum for borellia, tox-
oplasma, Cytomegalovirus and Epstein-Barrs virus. Cultural investigation of the 
ﬂ uid veriﬁ ed two colonies of the fungus Cryptococcus neoformans. Despite in-
travenous and intrathecal administration of antibiotics and steroids the patient 
died due to septic shock.
 Conclusions Prognosis of cryptococcosis is very serious especially in immunocompromised pa-
tients and in the case of disseminated form is always infaust.
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BACKGROUND
Chronic B-lymphatic leukaemia (B-CLL) is a 
slightly aggressive (malignant) lymphoprolipher-
ative disease originating on the basis of prolipher-
ation of clonal, malignant transformed mature B-
lymphocytes [1,2]. This type of leukaemia is the 
most frequent leukaemia of adults in Europe and 
North America, where it comprises 25–30% of all 
leukaemias. Its incidence in Europe is 3/100000; 
it occurs 2 times more frequently in men than 
women and usually in persons over the age of 50 
[3,4]. Probably lymphotropic viruses witch inhib-
ace apoptosis in an invaded B cell and the gene 
bcl-2 participate in aetiopathogenesis of B-CLL 
[5]. The result of its increased expression is the 
inhibition of apoptotic death of pathologic lym-
phocytes. The clinical picture of B-CLL is ex-
pressed with a long (at least ten years) asympto-
matic period. The only symptom of the disease 
in this period is lymphocytosis in the peripher-
al blood and bone marrow. Clinical stages of B-
CLL are classiﬁ ed by NCI-WG (National Cancer 
Institute – White Granulocytes) (it is a modiﬁ ca-
tion of the classiﬁ cation by Raie and Binet) [1,2]: 
1. B-CLL with low risk (lymphocytosis in periph-
eral blood), 2. B-CLL with medium risk (lym-
phocytosis in peripheral blood and lymphade-
nopathies or splenomegaly/hepatomegaly), 3. 
B-CLL with high risk (lymphocytosis in periph-
eral blood with anaemia (haemoglobin <110g/li-
tre) or with thrombocytopenia (number of throm-
bocytes <100×109/litre). The diagnosis of B-CLL 
is based on NCI-WG criteria [5]: 1. lymphocyto-
sis in peripheral blood (absolute number of lym-
phocytes is 5000/ml), 2. lymphocytes are small 
and mature with imunophenotype B1 (CD5+ 
B cells). The strategy of B-CLL therapy arises 
from the fact that treated in a traditional way it 
is an incurable disease. The therapy of B-CLL is 
indicated mainly at advanced stages of the dis-
ease and consists of systemic palliative chemo-
therapy [1–3]. Its aim is induction of apoptosis 
in B-CLL cells. Applied cytostatics include alky-
lac substances (chlorambucil) in monothera-
py or in combination with corticosteroids for si-
multaneous thrombocytopenia and autoimmune 
haemolytic anaemia. In recent years, purine an-
alogues (ﬂ udarabine monophosphate, 2-chlo-
rdeoxyadenozine) have been administered [5]. 
Haematopoietic stem cell transplantation and 
immunotherapy with monoclonal antibodies 
(anti-CD20 and anti-CD40) are also applied. The 
median survival time in patients with B-CLL, di-
agnosed at the initial phase, is 8–10 years [1,2]. 
Of essential importance in prognosis of B-CLL is 
the determination of chromosomal aberrations 
(deletion 11q23, trisomia 12) by means of FISH 
method (ﬂ uorescence in situ hybridization). A 
mutation of gene p53 is also associated with poor 
prognosis [1].
AIM
B-CLL is one reason for the development of sec-
ondary immunodeﬁ ciency due to the decrease 
of antibody immune activity (hypogammaglob-
ulinaemia) and the decrease of T-cell immuni-
ty. Immune system disorders include frequent 
infections, usually opportunistic and recidives 
of respiratory infections (bacterial, viral, fun-
gal, etc.) [3].
CASE REPORT
A 74-year-old man who presented with a four-year 
history of B-CLL with medium risk treated by cy-
clophosphamide in the dosage of 50mg daily to-
gether with prednison administered in the dose 
of 10mg daily was admitted to the Department of 
Clinical Haematology for further clinical, labo-
ratory and auxiliary investigations and therapeu-
tic intervention for suspected neuroinfection on 
November 20, 2004. The patient had headache, 
was sleepy and was meningeal.
First, magnetic resonance imaging of the brain 
was carried out verifying diffuse brain atrophy 
with leukoaraiosis picture. The picture does not 
verify progressive multifocal leukoencephalop-
athy. On November 20, 2004, the patient un-
derwent a neurological investigation with the 
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conclusion : 1. progradual apatico-abulic syn-
drome, prefrontal syndrome, upper meningeal 
syndrome, suspected tumorous inﬁ ltration men-
ing according to ﬂ uid, magnetic resonance not 
veriﬁ ed, 2. febrile status of unclear aetiology, un-
likely central cause. We performed lumbal punc-
ture. Microscopic, cytological and biochemical 
investigations of the cerebrospinal ﬂ uid were 
negative. Cultural investigation of ﬂ uid veriﬁ ed 
>10 colonies of the fungus Cryptococcus neofor-
mans. Also we performed investigations of blood 
serum for borellia, toxoplasma, Cytomegalovirus 
and Epstein-Barr virus. All investigations were neg-
ative. In the patient therapy was applied with in-
travenous amphotericin B in the dose of 50mg a 
day and intravenous empirically wide-spectrum 
antibiotic (Tazocine in the dose of 4.5 grams 3× 
a day). Dexamethasone in the dose of 4mg and 
amphotericin B in the dose of 0.05mg were ap-
plied intrathecally 1× a week. Before intrathecal 
application of dexamethasone and amphoter-
icin B we performed subscription of ﬂ uid to mi-
croscopic, cytological, biochemical and cultural 
investigations. On December 1, 2004, we per-
formed another control lumbal puncture dur-
ing intensive antimycotic therapy. Microscopic, 
cytological and biochemical investigations of the 
cerebrospinal ﬂ uid were negative. Cultural inves-
tigation of the ﬂ uid veriﬁ ed two colonies of the 
fungus Cryptococcus neoformans (regression of 
number of colonies) (Figures 1 and 2).
The patient’s therapy was retained without 
change. On December 17, 2004, the patient was 
meningeal and he was febrile. We performed fur-
ther control lumbal puncture. Microscopic, cy-
tological and biochemical investigations of ﬂ uid 
were negative. Cultural investigation of ﬂ uid veri-
ﬁ ed >10 colonies of the fungus Cryptococcus ne-
oformans (progression of number of colonies). 
For febrile status we completed cultural investi-
gations of the nose, neck, sputum, rectum, urine 
and haemoculture. For progression of B-CLL, cy-
clophosphamide was added to the system thera-
py in the dose of 100mg a day.
On December 20, 2004, due to the character of 
the disease – progradual cryptococcal neuroin-
fection in the immunocompromised patient 
through intensive casual therapy – it was nec-
essary to apply symptomatic therapy only. On 
December 21, 2004 at 15:40, the patient died 
due to septic shock (urosepsis with progradual 
cryptococcal neuroinfection) – autopsy proved 
cryptococcal meningitis.
DISCUSSION
Cryptococcosis (synonym: torulosis, European 
blastomycosis) is characterized as an infectious dis-
ease induced by Cryptococcus neoformans fungus 
usually with a primary focus in the lungs and with 
characteristic spread into the cerebral dura mater 
and rarely into the kidneys, prostate, liver, bones 
and skin. The disease occurs sporadically; 2 times 
more frequent incidence is proved in men at the 
age of 40–60 compared to women [4]. Frequent 
incidence was revealed in immunocompromised 
patients, above all in patients with AIDS or with 
haematological malignancies. The agent is spread 
in man’s environment mainly in soil substrates 
containing droppings of some birds (pigeons). 
The fungus’s hosts are man, cats, dogs, horses 
and primates. An infectious dose is signiﬁ cant 
for its low pathogenicity level in healthy adults. 
Route of transmission is especially through inha-
lation. The incubation period is not well known; 
in lung diseases and central nervous system dis-
orders months or even years are indicated. Brain 
damage includes above all diffuse meningitis, me-
ningela granulomes, brain infarctions and malat-
ic focuses. The most frequent symptom in men-
ingitis is cefalea with meningism manifestation. 
The patient usually makes an appointment with 
a physician for cefalea, visual disorders, psycho-
logical disorders – anxiety, depression, memory 
Figures 1–2. Cryptococcus neoformans fungus in electronic microscope with characterized mucopolysaccharide capsule.
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loss, concentration problems, psychomotor anx-
iety, dysartria, etc. [4]. Diagnosis of cryptococco-
sis is based on microscopic evidence of budding 
fungi surrounded by a light capsula in a prepa-
ration made from sputum, purulent exudate or 
cerebrospinal ﬂ uid. A speciﬁ c antigen may be de-
tected in blood, urine or liquor with latex agluti-
nation. The diagnosis of cryptococcosis is signiﬁ -
cantly proved by cultivation and identiﬁ cation of 
the infective agent.
The therapy of cryptococcal meningitis is based 
on systemic antimycotic therapy [4]. A combi-
nation of amphotericin B with 5-ﬂ ucytosin may 
be the drug of choice: amphotericin in the dose 
of 0.3mg/kg/day intravenously for a period of 6 
weeks, 5-ﬂ ucytosin in the dose of 150mg/kg/day 
per os in 4 partial doses for a period of 6 weeks 
[4]. This therapy is successful approximately in 
85% of patients without AIDS. In patients with 
AIDS, this therapy is successful only in 50%. Cured 
patients need a long-term and likely a whole-life 
suppressive therapy best of all with ﬂ uconazol in 
the dose of 200mg daily per os. Unfavourable ef-
fects of the above-mentioned antimycotic thera-
py are dyspeptic complaints, skin manifestations 
(unspeciﬁ ed dermatosis, anaemia, leukopenia 
and thrombocytopenia), elevation of liver trans-
mitases and nitrogenous catabolites. Prognosis of 
cryptococcosis is very serious especially in immu-
nocompromised patients and in the case of dis-
seminated form is always infaust.
CONCLUSIONS
In the present report we describe cryptococcosis 
of an immunocompromised patient as a rare and 
especially the incidence of cryptococcal menin-
gitis in an adult patient with chronic B-lymphat-
ic leukaemia with medium risk.
REFERENCES:
 1. Adam Z, Vorlicek J et al: Hematology Book. 
Malignant hematological diseases review. 1st ed. 
Prague: Grada, 2001: 677
 2. Andel M, Gregor P, Horak J et al: Internal Medicine 
– Volume IIIb – Hematology. 1st ed. Prague: Galen, 
2001: 230
 3. Klener P et al: Czech TextBook of Clinical Oncology. 
1st ed. Prague: Galen, 2002: 686
 4. Urbini B, Castellini C, Rondelli R et al: Cryptococcal 
meningitis during front-line chemotherapy for 
acute lymphoblastic leukemia. Haematol–Hematol 
J: 2000; 85: 1103–4
 5. Kvasnicka J, Kruzik P, Cmunt E et al: Substitutes 
of lymphocyte subpopulations in chronic B-lym-
phatic leukemia. Czech Pract, 1994; 133: 506–10
Case Report Rep Pract Oncol Radiother, 2007; 12(1): 61-64
64
